ãã€ãªå»è¬åäŒç€Ÿã§ãã Kala Pharmaceuticals, Inc. ã¯ãçŒçŸæ£ã®æ²»çã«ç¬èªã®ããç²åããŒã¹ã®ç²æ¶²æµžéç²å (MPP) æè¡ã䜿çšããæ²»çæ³ã®çºèŠãéçºãããã³åååã«éç¹ã眮ããŠããŸããå瀟ã®è£œååè£ã«ã¯ããã©ã€ã¢ã€ã®å
åãšçç¶ã®çææ²»ççšã® EYSUVISãçŒç§æè¡åŸã®è¡åŸççãšçŒçã®æ²»ççšã® 1 æ¥ 2 åã®å±æçŒã¹ããã€ãã§ãã INVELTYS ãªã©ããããŸããå瀟ã®åèšåºéçºããã°ã©ã ã«ã¯ãããŸããŸãªç¶²èçŸæ£ã®æ²»ççšã®å容äœããã·ã³ãããŒãŒé»å®³å€ããã°ã©ã ã§ãã KPI-285/KPI-286ããã©ã³ã¹æŽ»æ§åçµè·¯ãåé¿ããªãããã©ã³ã¹æå¶çµè·¯ãä»ããŠéºäŒåçºçŸãå¶åŸ¡ããããã«èšèšãããæ°ããã¯ã©ã¹ã®ååç©ã§ãã SEGRM ããã°ã©ã ãããã³çŒè¡šé¢ãæšçãšãã屿ã¹ããã€ããšããŠã®æ°ããååŠç©è³ªã§ããè¡šé¢æšçã¹ããã€ã ããã°ã©ã (KPI-333) ãå«ãŸããŸããå瀟ã¯ä»¥åã¯Hanes Newco, Inc.ãšããŠç¥ãããŠããŸãããã2009幎12æã«Kala Pharmaceuticals, Inc.ã«ç€Ÿåã倿ŽããŸãããKala Pharmaceuticals, Inc.ã¯2009幎ã«èšç«ãããããµãã¥ãŒã»ããå·ãŠã©ãŒã¿ãŒã¿ãŠã³ã«æ¬ç€Ÿã眮ããŠããŸãã